BRAF and melanoma: The five-year analysis of adjuvant dabrafenib and trametinib in patients with resected stage III BRAF V600-mutant melanoma confirmed the long-term benefit of the treatment with median RFS not being reached for dabrafenib and trametinib vs. 16.6 months in the placebo arm [28].